7 Emerging Trends Shaping Clinical Labs in 2026

As clinical laboratories head into 2026, accelerating advances in artificial intelligence (AI), genomics, diagnostics, and operational efficiency are reshaping how labs deliver value across health care and life sciences. 

Insights from industry experts, researchers, and technology leaders point to a year defined not by incremental change, but by convergence—of data, automation, and patient-centric care.

Here are the seven key trends lab leaders should watch in 2026:

1. AI will move from decision support to diagnostic partner

AI will evolve beyond traditional decision support, becoming a true diagnostic collaborator. William Morice, MD, PhD, CEO of Mayo Clinic Laboratories, predicts that augmented diagnostics will increasingly rely on collaboration between humans and AI, with labs deciding when to keep humans in the loop and when to automate.

Jonathan Kron, CEO of BloodGPT, adds that in 2026, “assistants and workflow automations will move from ‘answering’ to doing—placing orders, scheduling, checking coverage, and documenting.” He emphasizes that clinicians will still need to oversee these processes, as overly simplistic apps can create fatigue, while all-in-one “super-apps” risk overpromising and under-delivering. “The winning model will be a composable layer: specialist modules that plug into existing structures (EHR, lab, payer) and show up inside the tools clinicians already use,” he says.

2. Data governance will become a strategic imperative

As AI adoption grows, labs will need to strengthen data governance, interoperability, and security. Centralized AI training data will expose vulnerabilities, and patient concerns around privacy and compliance will intensify. Labs that implement strong frameworks for data sharing and protection will build trust and gain a competitive edge.

Morice emphasizes that labs need to be proactive in anticipating challenges and regulatory headwinds that come with innovation: “With the court decision that lab developed tests are not medical devices, everyone took a big, deep breath. But the reality is labs have to keep their ears to the ground about regulatory aspects,” he says. 

“Think about software as a medical device. As we develop tools that work off clinical lab data, what are going to be some of the regulatory headwinds? Labs should be forming deep relationships with tech purveyors and manufacturers, because they’re driving a lot of this innovation. Think about the headwinds those companies might face. How can labs help lower those barriers by anticipating them? That can add value for the laboratory.”

• Read more: Fixing the Data Disconnect in Clinical Laboratories

3. Genomics and multi-omics will drive personalized diagnostics

Clinical laboratories are moving toward a more holistic understanding of patient biology by integrating genomics, proteomics, and other complex data streams. 

Morice highlights the growing accessibility and sophistication of these tools: 

“Today is an exciting time in diagnostics when you think about the tools that are now available to provide diagnostic information. For example, mass spectrometry is becoming more adopted into clinical workflows; in vitro diagnostic companies are manufacturing automated instruments; and we’re just hitting that precipice of in-depth genomic sequencing being more widely available. I also think about proteomics, which is linked to mass spec. There is sophistication around immunoassays derived from proteomics.”

 

Building on this, Matthew Oberley, MD, PhD, senior VP and chief clinical officer at Caris Life Sciences, points to the growing clinical utility of liquid biopsy:

“In 2026, liquid biopsy will gain greater clinical utility as laboratories refine how they differentiate true tumor-derived signals from background genomic noise. Improvements in assay design, bioinformatic filtering, and expert molecular interpretation will help ensure that results more accurately reflect a patient’s real disease biology.”

Together, these insights highlight how multi-omics approaches and advanced molecular testing are enabling more precise, personalized diagnostics, shaping the future of patient-centered care in 2026.

4. Patient-driven diagnostics will expand beyond traditional care settings

In 2026, diagnostics will increasingly extend beyond traditional clinical environments. Wearables, connected devices, and AI health tools will empower patients to generate clinically relevant data from home. 

Morice notes that what began as wellness tracking is becoming integral to clinical decision-making, challenging labs to integrate patient-generated data while maintaining accuracy and reliability. “The sweet spot is for lab leaders to think about pilot programs for wearables that might be happening in their health systems. There are a lot of pilots out there,” he says.

• Read more: Evaluating the Potential of Point-of-Care Testing in Clinical Trials

5. Operational efficiency will become core to quality

With staffing pressures and growing test complexity, clinical labs are focusing on optimizing workflows, automation, and consistent processes. 

“Clinical labs will spend 2026 sharpening the parts of their workflow that have the biggest day-to-day impact,” says Greer Massey, PhD, chief scientific officer at Molecular Designs. “Teams are leaning into simpler, more consistent processes, like ready-to-use PCR panels, automation, and fewer manual steps, to protect turnaround times even when staffing is tight. Multiplex testing will continue to expand as labs look for ways to deliver more insight from the same sample without slowing down. The labs that thrive will be the ones that treat operational efficiency as a core part of quality, using small, meaningful improvements to drive faster, more dependable results.”

Adding perspective from operations at a major lab, Morice advises that “if you’re a single lab, now is the time to start communicating with your clinical partners about test utilization. Look at how to optimize your laboratory’s performance.” 

“On the other hand, if you’re part of a large, multisystem hospital or network, think about how you can start to consolidate within your laboratory,” he says. “Also, communicate with your C-suite, if possible, because unfortunately, there is a tendency for hospital management outside of the laboratory to look at the lab as a cost center.”

By combining automation, workflow refinement, and proactive communication, labs can maintain quality, improve efficiency, and better handle regulatory and financial pressures in 2026. 

6. Clinical research and drug development collaborations

Labs are increasingly positioned as strategic partners for biopharma, guiding patient selection and therapeutic decisions. Julia Tarasenko, chief commercial and strategy officer at LabConnect, notes that AI and automation are transforming clinical trials, streamlining everything from patient recruitment to sample handling. These innovations help new treatments reach patients faster and allow smaller companies to compete with larger pharmaceutical firms.

At Mayo Clinic Laboratories, Morice highlights how lab leaders are using their data to support biopharma efforts:

“Another opportunity is to look at the needs of biopharma. Labs hold the keys for a lot of different things for biopharma, such as companion diagnostics. With the full body of lab data, how can that be used to identify patients that are eligible for drugs but not getting them? That’s a huge problem to solve. As we see more use of these companion drugs, we need to better understand the responders who show a beneficial outcome with the drug versus non-responders who don’t show a beneficial outcome. As opposed to waiting for the therapeutics to come to the patients, we need to create a lab response to help guide the use of therapeutics.”

This example highlights how labs are expanding beyond traditional diagnostics, leveraging data and technology to play a more active role in clinical research and personalized medicine.

• Read more: Unlocking Clinical Trial Data: Driving Smarter Decisions in Safety, Compliance, and Trial Design

7. GLP-1 therapies will continue to reshape metabolic care

GLP-1 therapies have transformed the pharmaceutical landscape, evolving from diabetes treatments into a leading approach for metabolic health. Their success has elevated obesity from a secondary focus to one of the industry’s most dynamic areas of innovation and investment. 

Hyung Heon Kim, CEO of MetaVia, highlights that while GLP-1s are changing treatment paradigms, gaps remain for certain patients:

“About 20 percent of type 2 diabetes patients cannot tolerate or do not respond to GLP-1 therapies. The next wave of innovation will address these unmet needs through combination and oral approaches, pairing GLP-1 activity with other mechanisms to improve efficacy and tolerability.”

Looking ahead, the market will likely focus on factors such as dosing convenience, speed of titration, and oral formulations, which can improve access, adherence, and cost efficiency. These innovations suggest that GLP-1 therapies will continue to expand treatment possibilities for diabetes and obesity, driving patient-centric care in 2026 and beyond.

A related area for labs to monitor: Heavy utilization of expensive GLP-1 drugs are also driving up consumer costs for health insurance, The Washington Post reported on September 12.

• Read more: Precarious Prescriptions: Lab Testing and Coverage for GLP-1 Drugs

Looking ahead

As 2026 approaches, clinical labs and biopharma are entering a period of rapid innovation. From AI-driven diagnostics and multi-omics to patient-centric therapies and next-generation GLP-1 treatments, these trends illustrate how technology, data, and collaboration are reshaping the industry. By embracing automation, genomics, and strategic partnerships, labs can not only improve patient outcomes but also play a more central role in driving research, precision medicine, and operational efficiency. The year ahead promises both challenges and opportunities, rewarding labs that combine scientific expertise with forward-thinking strategies.